ETF盘中资讯｜大权重发力，医疗快速翻红，512170溢价涨逾1.4%！资金连续12日加码，累计增仓超26亿元

Core Viewpoint - The healthcare sector is experiencing a significant rebound, with the largest healthcare ETF (512170) showing strong performance and attracting substantial capital inflows, indicating renewed investor interest in the sector [1][3][4]. Group 1: ETF Performance - The healthcare ETF (512170) rose over 1.4% after recovering from previous lows, successfully surpassing the 5-day and 60-day moving averages [1]. - The ETF has seen a continuous premium in trading, reflecting active buying interest, with a net inflow of 2.688 billion yuan over the last 12 trading days [3]. Group 2: Earnings Forecasts - As of now, 18 constituent stocks of the healthcare ETF have disclosed their earnings forecasts for 2025, with 11 expected to report profits. Notably, 12 stocks are projected to achieve double-digit growth [4]. - Specific companies like Lepu Medical are forecasting a net profit increase of 224% to 3.86 billion yuan, while other leading CXO firms like Zhaoyan New Drug and Boteng Co. are also expected to see substantial profit growth [4][5]. Group 3: Market Trends - The recovery in the global investment landscape, ongoing domestic support for the innovative drug sector, and a revival in new drug development are contributing to a positive outlook for the CXO industry [4]. - By 2026, structural reforms and improved policy and financing environments are expected to drive the Chinese pharmaceutical industry towards high-quality development [4]. Group 4: ETF Characteristics - The healthcare ETF (512170) is the largest in the market, with a fund size of 27.5 billion yuan, covering over 50% in medical devices and nearly 25% in CXO [6]. - The ETF includes 12 stocks related to AI medical and brain-computer interface concepts, providing a diversified investment opportunity in the healthcare sector [6].